CLINICAL PROGRESSION OF RHEUMATOID ARTHRITIS AND HEMOVASCULAR REMODELING: ASSOCIATIONS BETWEEN SEROSTATUS, FUNCTIONAL CLASS, ENDOTHELIAL DYSFUNCTION AND HEMOSTATIC ACTIVITY

DIGITAL OBJECT IDENTIFIER (DOI): https://doi.org/10.67620/sai.57d0004
Musaeva N1
1 Tashkent State Medical University, Department of Hematology, Transfusiology and Laboratory Medicine
ReceivedJul 05, 2026
RevisedJul 20, 2026
PublishedJul 25, 2026

Annotatsiya

Rheumatoid arthritis is a systemic autoimmune disease whose progression is frequently accompanied by vascular inflammation, endothelial dysfunction, and hemostatic imbalance. This study assessed the relationships among disease duration, serological status, American College of Rheumatology functional class, platelet hemostasis, coagulation abnormalities, and endothelial dysfunction. The study included 85 patients with rheumatoid arthritis and 30 healthy controls. Patients were classified into three groups according to disease duration: up to 6 months (n = 24), 6 months to 1 year (n = 33), and more than 2 years (n = 28). Serostatus, functional class, platelet indices, coagulation parameters, and endothelial dysfunction markers were analyzed. The proportion of seronegative rheumatoid arthritis declined from 45.8% in the first group to 39.4% in the second and 28.6% in the third, whereas seropositive disease increased to 71.4% among patients with disease duration exceeding 2 years. The frequency of functional classes I and II decreased as disease duration increased, while classes III and IV became progressively more common. Platelet hemostatic activity was most pronounced during the first year of disease, whereas coagulation abnormalities became more prominent in patients with longer disease duration. Endothelial dysfunction persisted across all groups. These findings indicate that rheumatoid arthritis progression is associated with a transition from early platelet-dominant activation to later coagulation-dominant hypercoagulability, while endothelial dysfunction remains present throughout the disease course. Seropositive status and advanced functional limitation may therefore characterize a more severe hemovascular phenotype..

Kalit so'zlar

rheumatoid arthritis, serostatus, functional class, endothelial dysfunction, hemostasis, D-dimer, endothelin-1, von Willebrand factor.

Foydalanilgan adabiyotlar

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588. https://doi.org/10.1136/ard.2010.138461. 2. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. https://doi.org/10.1136/ard-2022-223356. 3. Yang XZ, Chang Y, Wei W. Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediators Inflamm. 2016;2016:6813016. https://doi.org/10.1155/2016/6813016. 4. Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial dysfunction in patients with rheumatoid arthritis: the role of hypertension. Curr Hypertens Rep. 2020;22(8):56. https://doi.org/10.1007/s11906-020-01064-y. 5. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis. 2002;61(9):804-809. https://doi.org/10.1136/ard.61.9.804. 6. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-1193. https://doi.org/10.1111/j.1538-7836.2006.01949.x. 7. Manz XD, Doddaballapur A, Hynes RO, Wagner DD. Regulation of VWF (von Willebrand factor) in inflammatory thrombosis. Arterioscler Thromb Vasc Biol. 2022;42(11):1307-1320. https://doi.org/10.1161/ATVBAHA.122.318179. 8. Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169-175. https://doi.org/10.1136/annrheumdis-2020-218419. 9. Hu LJ, Ji B, Fan HX. Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(22):7005-7013. https://doi.org/10.26355/eurrev_202111_27249. 10. Omair MA, Alkhelb SA, Ezzat SE, Boudal AM, Bedaiwi MK, Almaghlouth I. Venous thromboembolism in rheumatoid arthritis: the added effect of disease activity to traditional risk factors. Open Access Rheumatol. 2022;14:231-242. https://doi.org/10.2147/OARRR.S284757. 11. Södergren A, Karp K, Boman K, Eriksson C, Lundström E, Smedby T, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima-media thickness. Arthritis Res Ther. 2010;12(4):R158. https://doi.org/10.1186/ar3116. 12. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004;63(1):31-35. https://doi.org/10.1136/ard.2003.007740. 13. Bordy R, Totoson P, Prati C, Marie C, Wendling D, Demougeot C. Microvascular endothelial dysfunction in rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(7):404-420. https://doi.org/10.1038/s41584-018-0022-8. 14. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449-1455. https://doi.org/10.1002/art.39098. 15. Jiang SZ, To JL, Hughes MR, McNagny KM, Kim H. Platelet signaling at the nexus of innate immunity and rheumatoid arthritis. Front Immunol. 2022;13:977828. https://doi.org/10.3389/fimmu.2022.977828.

Maqolaga iqtibos keltirish andozasi

Musaeva N (2026). CLINICAL PROGRESSION OF RHEUMATOID ARTHRITIS AND HEMOVASCULAR REMODELING: ASSOCIATIONS BETWEEN SEROSTATUS, FUNCTIONAL CLASS, ENDOTHELIAL DYSFUNCTION AND HEMOSTATIC ACTIVITY. Science and Innovation, 5(7), 31-36. https://doi.org/10.67620/sai.57d0004